Your Goals and the Added Values of Your ATMP
When you develop an ATMP, you do it with a specific group of patients in mind. Still, it is important to look further. Is this the only patient group? Will healthcare professionals use and prescribe your ATMP to your patients? Will your ATMP be reimbursed? This requires some research into the therapeutic options for your patients and their caregivers. That is why it is important to start with a good brainstorm. In this topic Marc Dechamps proposes a number of questions that can help. He also suggests some working methods that can support you in important parts of your planning.
The Speaker
Marc Dechamps
Marc Dechamps is a biologist with over 35 years of experience in the pharmaceutical industry. Marc founded XMF Consulting in 2016. Marc is also chairman of CEBR, the Council of European BioRegions, member of the advisory board of eu.reca and International Affairs Representative of BioWin. Marc previously held positions as Managing Director of Delphi Genetics and interim CEO of eTheRNA Immunotherapies.
The Company
XMF Consulting
XMF Consulting provides strategic advice and management support to companies active in the Healthcare and Life Sciences sector. With over 35 years of experience defining strategies and operations, managing businesses and leading focused, multi-skilled and multicultural teams, XMF Consulting supports, advises and empowers small and medium-sized biotechnology and biopharmaceuticals and pharmaceutical companies.